首页> 外文期刊>Cancer and Metastasis Reviews >Protein tyrosine phosphatase epsilon and Neu-induced mammary tumorigenesis.
【24h】

Protein tyrosine phosphatase epsilon and Neu-induced mammary tumorigenesis.

机译:蛋白酪氨酸磷酸酶ε和Neu诱导的乳腺肿瘤发生。

获取原文
获取原文并翻译 | 示例
       

摘要

Aberrant regulation of the phosphorylation of proteins on tyrosine residues is a well-established cause of cancer. Protein tyrosine phosphatases (PTPs) share in the crucial function of maintaining appropriate levels of phosphorylation of cellular proteins, making them potentially key players in regulating the transformation process. The receptor-type tyrosine phosphatase Epsilon (RPTPepsilon) participates in supporting the transformed phenotype of mammary tumor cells induced in vivo by the Neu tyrosine kinase. The phosphatase is overexpressed in mammary tumors induced in mice by a Neu transgene and expression of RPTPepsilon in mouse mammary glands leads to massive hyperplasia and associated tumorigenesis. Furthermore, cells isolated from mammary tumors induced by Neu in mice genetically lacking RPTPepsilon appear less transformed and proliferate less well than corresponding mammary tumor cells isolated from mice expressing the phosphatase. At the molecular level, RPTPepsilon dephosphorylates and activates Src and the related kinases Yes and Fyn, and the activities of these kinases are significantly reduced in tumor cells lacking RPTPepsilon. Restoring the activities of these kinases reveals that it is only the reduced activity of Src that causes the aberrant morphology and proliferation rate of tumor cells lacking RPTPepsilon. RPTPepsilon is primed to activate Src, and presumably related kinases, following its phosphorylation by Neu at Y695 within its C-terminus. This event is crucial in enabling RPTPepsilon to activate Src, but appears not to affect the activity of RPTPepsilon towards unrelated substrates. We conclude that a Neu-RPTPepsilon-Src pathway exists in mouse mammary tumor cells, in which Neu phosphorylates RPTPepsilon thereby driving the phosphatase to specifically activate Src family kinases and to assist in maintaining the transformed phenotype.
机译:酪氨酸残基上蛋白质磷酸化的异常调节是众所周知的癌症原因。蛋白质酪氨酸磷酸酶(PTP)在维持细胞蛋白质适当磷酸化水平的关键功能中具有共同作用,使其成为调节转化过程的潜在关键角色。受体型酪氨酸磷酸酶Epsilon(RPTPepsilon)参与支持由Neu酪氨酸激酶在体内诱导的乳腺肿瘤细胞的转化表型。磷酸酶在Neu诱导的小鼠乳腺肿瘤中过表达,RPTPepsilon在小鼠乳腺中的表达导致大量增生和相关的肿瘤发生。此外,与从表达磷酸酶的小鼠分离的相应乳腺肿瘤细胞相比,在遗传上缺乏RPTPepsilon的小鼠中从Neu诱导的乳腺肿瘤分离的细胞表现出更少的转化和增殖。在分子水平上,RPTPepsilon会去磷酸化并激活Src和相关的激酶Yes和Fyn,而在缺乏RPTPepsilon的肿瘤细胞中,这些激酶的活性会大大降低。恢复这些激酶的活性表明,只有Src活性降低才导致缺乏RPTPepsilon的肿瘤细胞的异常形态和增殖速率。 RPTPepsilon在其C端的Y695处被Neu磷酸化后,被激活以激活Src和大概相关的激酶。此事件对于使RPTPepsilon激活Src至关重要,但似乎并不影响RPTPepsilon对无关底物的活性。我们得出结论,Neu-RPTPepsilon-Src途径存在于小鼠乳腺肿瘤细胞中,其中Neu磷酸化RPTPepsilon,从而驱动磷酸酶特异性激活Src家族激酶并协助维持转化的表型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号